Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetazolamide is a first-generation carbonic anhydrase inhibitor used to treat glaucoma (open-angle, secondary, and acute angle-closure), edema (fluid retention) caused by heart failure or other medications, certain types of epilepsy (including petit mal and unlocalized seizures), idiopathic intracranial hypertension, periodic paralysis, and to prevent or alleviate symptoms of altitude sickness. It works by inhibiting the enzyme carbonic anhydrase in the kidneys and eyes, leading to increased urine production (diuresis) and decreased intraocular pressure. It may also be used off-label for other conditions such as Ménière’s disease and central sleep apnea[1][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetazolamide.